- Home Page
- » On-Demand CME Activities
- » Hematology-Oncology
- » Ask the Expert: Addressing the Current Challenges of Multiple Myeloma Treatment
Ask the Expert: Addressing the Current Challenges of Multiple
Release date: March 22, 2013
Expiration date: March 22, 2014
Estimated time to complete activity: 1 hour
Jointly sponsored by
Support for this activity has been provided through educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, Merck Sharp & Dohme Corporation, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals.
This CME-certified activity is based on information presented at a CME satellite symposium held on December 7, 2012 in Atlanta, Georgia.
- Active Internet connection
To achieve optimal results, oncologists who treat multiple myeloma must be adept in individualizing patient management strategies, which includes stratifying patients based on risk and maximizing the depth and duration of treatment response. Oncologists also need to be aware of these approaches in the context of relapsed or refractory disease and the next generation of agents that may be useful for patients that become resistant to current regimens.
This activity has been designed to meet the educational needs of hematologist-oncologists and medical oncologists involved in the care of patients with multiple myeloma.
Upon completion of this activity, participants should be able to:
- Use cytogenetics, fluorescence in situ hybridization (FISH), and gene expression profiling to define patient prognosis and risk stratification
- Outline a treatment plan to achieve the desired response while balancing the risk for toxicities in high-risk and standard-risk myeloma patients
- Implement evidence-based strategies to prolong the duration of response in multiple myeloma patients
- Incorporate current consensus recommendations, guidelines, and the latest clinical evidence in the management of multiple myeloma
- Evaluate clinical data regarding the use of new agents in patients who develop resistance to or relapse from their initial therapy
Paul G. Richardson, MD—Program Chair
RJ Corman Associate Professor of Medicine
Harvard Medical School
Clinical Director, Jerome Lipper Center for Multiple Myeloma
Dana-Farber Cancer Institute
Faith Davies, MBBCh, MRCP, MD, FRCPath
Cancer Research UK Senior Cancer Fellow
Royal Marsden Hospital
Institute of Cancer Research
London, United Kingdom
Johannes Drach, MD
Professor of Medicine, Hematology and Oncology
Program Director, Multiple Myeloma and Malignant Lymphoma
Medical University of Vienna
Department of Medicine I/Clinical Division of Oncology
Andrzej Jakubowiak, MD, PhD
Professor of Medicine
Director, Myeloma Program
The University of Chicago
María-Victoria Mateos, MD, PhD
University Hospital of Salamanca
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine, Curatio CME Institute, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participation in this CME activity. To receive credit during the period March 22 2013 to March 22, 2014, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the posttest and activity evaluation, including the certificate information section.
To obtain a certificate, participants must receive a score of 70% or better on the posttest. The posttest can be accessed at the end of the activity. Please e-mail any questions to firstname.lastname@example.org. For questions about CME credit for this activity, contact Penn State at ContinuingEd@hmc.psu.edu or (717) 531-6483. Reference course # G5137-13-T
The Internet was selected as the medium to accommodate the learning preferences of a significant portion of the target audience.
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Faith Davies, MBBCh, MRCP, MD, FRCPath, has disclosed the following relevant financial relationships:
|Speaker and Advisory Board||Celgene, Janssen, Lilly, Merck Sharp & Dohme Corporation, Millennium: The Takeda Oncology Company, Novartis|
Dr. Davies discusses the unlabeled or investigational use of a commercial product.
Johannes Drach, MD, has disclosed the following relevant financial relationships:
|Consultant, Speaker||Celgene, Janssen|
Dr. Drach discusses the unlabeled or investigational use of a commercial product.
Andrzej Jakubowiak, MD, PhD, has disclosed the following relevant financial relationships:
|Advisory Board||Bristol-Myers Squibb, Celgene, Millennium: The Takeda Oncology Company, Onyx|
|Consultant||Bristol-Myers Squibb, Celgene, Millennium: The Takeda Oncology Company, Onyx|
Dr. Jakubowiak discusses the unlabeled or investigational use of a commercial product.
María-Victoria Mateos, MD, PhD, has disclosed the following relevant financial relationships:
|Consultant||Bristol-Myers Squibb, Celgene, Janssen, Millennium: The Takeda Oncology Company, Mundipharma, Onyx|
Dr. Mateos discusses the unlabeled or investigational use of a commercial product.
Paul G. Richardson, MD, has disclosed the following relevant financial relationships:
|Advisory Board||Bristol-Myers Squibb, Celgene, Johnson & Johnson, Millennium: The Takeda Oncology Company, Novartis|
Dr. Richardson discusses the unlabeled or investigational use of a commercial product.
Curatio CME Institute
Denise C. LaTemple, PhD, President, Curatio CME Institute, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
Anne Quinn Young, MPH, Vice President, Communications, has disclosed no relevant financial relationships.
Penn State College of Medicine
Faculty and staff involved in the planning and review of this activity have nothing to disclose.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Policy on Privacy and Confidentiality
Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, Penn State College of Medicine, the Multiple Myeloma Research Foundation, Amgen, Bristol-Myers Squibb, Celgene Corporation, Merck Sharp & Dohme Corporation, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, Penn State College of Medicine, the Multiple Myeloma Research Foundation, Amgen, Bristol-Myers Squibb, Celgene Corporation, Merck Sharp & Dohme Corporation, Millennium: The Takeda Oncology Company, or Onyx Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|Generic Name||Trade Name||Approved Use (if any)||Unapproved/Investigational Use|
|Bendamustine||Treanda||Treatment of patients with chronic lymphocytic leukemia; treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen||Treatment of multiple myeloma (MM)|
|Bortezomib||Velcade||Treatment of patients with MM||Maintenance therapy|
|Carfilzomib||Kyprolis||Treatment of patients with MM who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy||Frontline therapy|
|Elotuzumab||NA||NA||Treatment of MM|
|Everolimus||Afinitor||Treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib||Treatment of MM|
|Lenalidomide||Revlimid||Treatment of MM, in combination with dexamethasone, in patients who have received at least one prior therapy||Frontline therapy; maintenance therapy|
|Perifosine||NA||NA||Treatment of MM|
|Pomalidomide||Pomalyst||Treatment of patients with MM who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy||Frontline therapy|
|Temsirolimus||Torisel||Treatment of advanced renal cell carcinoma||Treatment of MM|
|Thalidomide||Thalomid||Treatment of patients with newly diagnosed MM in combination with dexamethasone||Relapsed/refractory MM; frontline therapy in combination with melphalan-prednisone; maintenance therapy|